Back

PCSK9 inhibitors: ready to embrace? Conclusion.

29 August 2016 (12:15 - 12:30)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: ready to embrace? Drug therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Heinz Drexel

Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch (Austria)

4 More presentations in this session

Presentation thumbnail
PCSK9 inhibitors: ready to embrace? - Positioning of the topic
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
PCSK9 inhibitors are ready for daily life clincial use - PRO
Professor E. Navarese (Sassari, IT)
Slides Video
Presentation thumbnail
PCSK9 inhibitors are ready for daily life clincial use - CON
Professor T. Pedersen (Oslo, NO)
Slides Video
Presentation thumbnail
PCSK9 inhibitors are ready for daily life clincial use -Discussion PRO/CONTRA.
Video

Access the full session

Session thumbnail
PCSK9 inhibitors: ready to embrace?

The Event

Event poster

ESC Congress 2016

29 August 2016 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
1 September 2025
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes
1 September 2025
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022
thumbnail
Congress Presentation
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources